Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU
Avatar photo

Celularity Inc.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.
Avatar photo
Celularity Inc. 10 Jun 2025
0

Celularity Announces Chief Financial Officer Transition

...
in
Press Releases
1144
Avatar photo
Celularity Inc. 2 Jun 2025
0

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

...
in
Press Releases
1142
Avatar photo
Celularity Inc. 9 May 2025
0

Celularity Announces Full Year 2024 Operating and Financial Results

...
in
Press Releases
1147
Avatar photo
Celularity Inc. 14 Apr 2025
0

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

...
in
Press Releases
1142
Avatar photo
Celularity Inc. 7 Apr 2025
0

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

...
in
Press Releases
1145
Avatar photo
Celularity Inc. 25 Feb 2025
0

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

...
in
Press Releases
1137
Avatar photo
Celularity Inc. 24 Feb 2025
0

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

...
in
Press Releases
1128
Avatar photo
Celularity Inc. 27 Jan 2025
0

MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs

...
in
Press Releases
1125
Avatar photo
Celularity Inc. 6 Dec 2024
0

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

...
in
Press Releases
1123
Avatar photo
Celularity Inc. 7 Nov 2024
0

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

...
in
Press Releases
1120
Avatar photo
Celularity Inc. 23 Oct 2024
0

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

...
in
Press Releases
1130
Avatar photo
Celularity Inc. 22 Oct 2024
0

Celularity Provides Corporate Update

...
in
Press Releases
1116
Avatar photo
Celularity Inc. 16 Oct 2024
0

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

...
in
Press Releases
1121
Avatar photo
Celularity Inc. 5 Sep 2024
0

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

...
in
Press Releases
1117
Avatar photo
Celularity Inc. 28 Aug 2024
0

Celularity Appoints Richard J. Berman to its Board of Directors

...
in
Press Releases
1121
Avatar photo
Celularity Inc. 31 Jul 2024
0

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

...
in
Press Releases
1133
Avatar photo
Celularity Inc. 3 Jun 2024
0

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

...
in
Press Releases
1132
Avatar photo
Celularity Inc. 14 May 2024
0

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

...
in
Press Releases
1110
Avatar photo
Celularity Inc. 22 Apr 2024
0

Celularity Inc. to Host Investor and Analyst Research & Development Day

...
in
Press Releases
1117
Avatar photo
Celularity Inc. 18 Apr 2024
0

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

...
in
Press Releases
1098
Load more
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions

in
F.A.Q
Support Forum
Video Tutorials

Search panel can contain any widgets and shortcodes.

Call us: (908) 768 – 2170